This analysis presents a path forward for the expansion of VBC to promote orphan drug development, expand access to pharmaceuticals, and improve patient safety and explores different contracting options and paths for organizations like CMS and integrated payer-provider networks.
Abstract
The onset of improved data interoperability required as a result of the 21st Century Cures Act, 92% Health Information Exchange coverage, and lessons learned from European pharmaceutical risk-sharing models present innovative and timely opportunities for the U.S. to adopt pharmaceutical value-based contracting (VBC), which uses drug-level performance to allocate financial risk between payers and manufacturers based on clinical and economic metrics. Having been piloted in Italy, Spain, and the UK, this analysis explores different contracting options and paths for organizations like CMS and integrated payer-provider networks to draw on these lessons to adapt VBC frameworks to the U.S. pharmaceutical landscape. While advances have been seen in other areas of VBC and rising net drug costs year-over-year, only 2.3% of publicly available pharmaceutical VBC contracts have been deployed in the U.S. as compared to 77.9% in Europe. As such, we present a path forward for the expansion of VBC to promote orphan drug development, expand access to pharmaceuticals, and improve patient safety.
These findings illustrate how the broad use of managed access mechanisms can support balancing access to innovation with health system sustainability, and identify the most effective managed access strategies to facilitate access to new HIMs at costs sustainable for health systems.
E. L. Gispert, D. Gay, M. Fontanet et al.· Health Policy OPEN· 0 citations
Canada has an opportunity to learn from best practices in other jurisdictions to streamline reimbursement pathways and provide earlier, equitable access to new therapies for a greater number of patients, including specific access challenges associated with new dermatological treatments.
Maxwell Sauder, M. Ponzo· Canadian Dermatology Today· 0 citations
Abstract Drug prescription is a complex decision for physicians, and pharmaceutical firms may influence prescription behaviour through payments. Such incentives may lead to better prescriptions, but also to low-value choices. To mitigate these risks, some countries have mandated the public disclosure of industry paym...
H. Vasconcelos, J. Diniz, A. Moura et al.· European Journal of Public H...· 0 citations
The Clinical Costing framework and its components—Health Activity Costing, Health Performance Costing, Patient Level Costing, and Health Management Costing—are described along with the experience of the Italian Healthcare Network (N.I.San.), which annually validates and processes hospital discharge data.
Marco Claus, Fabio Zorzetto· ABOUTOPEN· 0 citations
BACKGROUND
Health systems worldwide face mounting pressure to deliver better outcomes with constrained resources. Improving productivity therefore depends not only on operational efficiency but also on payment approaches that align incentives with value. Value-Based Payment (VBP) models seek to reward quality and effic...
Ana Moreira, José Crispim· Health Policy· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.